Nicaragua
Tuberculosis profile
Population  2013 6.1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.16 (0.12–0.21) 2.7 (2–3.5)
Mortality (HIV+TB only) 0.016 (0.011–0.022) 0.26 (0.18–0.36)
Prevalence  (includes HIV+TB) 4.1 (1.7–7.7) 68 (28–126)
Incidence  (includes HIV+TB) 3.4 (3.1–3.6) 55 (51–60)
Incidence (HIV+TB only) 0.11 (0.1–0.12) 1.8 (1.7–1.9)
Case detection, all forms (%) 87 (81–96)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.6 (0.1–2.2) 11 (6.2–17)
MDR-TB cases among notified pulmonary
TB cases
15 (2–54) 21 (12–33)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 540   122
Pulmonary, clinically diagnosed 904    
Extrapulmonary 386    
       
Total new and relapse 2 952    
Previously treated, excluding relapses 76    
Total cases notified 3 028    
Among 1 540 new cases:
59 (4%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 9 (<1%) 75 (38%) 84
Laboratory-confirmed RR-/MDR-TB cases     20
Patients started on MDR-TB treatment     15
TB/HIV 2013 Number (%)
TB patients with known HIV status 2 094 (69)
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 327  
HIV-positive people provided with IPT 126  
Treatment success rate (%)
New cases registered in 2012 87
Previously treated cases registered in 2012  
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 30
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 3.1
Culture (per 5 million population) 2.5
Drug susceptibility testing (per 5 million population) 0.8
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 5.8
% Funded domestically 43%
% Funded internationally 43%
% Unfunded 14%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-02 Data: www.who.int/tb/data